New technologies developed for treatment of premature ejaculation.
Arik ShechterIlan GruenwaldPublished in: International journal of impotence research (2024)
Premature ejaculation (PE), lifelong and acquired, is the most common male sexual disorder, with serious impacts on the patient and his partner's quality of life, sexual well-being, and psychosocial health. The most popular treatment options are on-demand topical anesthetics and off-label daily or on-demand selective serotonin reuptake inhibitors (SSRIs), followed by behavioral therapy. While SSRI treatments are reportedly safe, they are associated with limited efficacy and provide only a temporary delay in ejaculation latency time. The majority of PE patients are dissatisfied with SSRIs; thus, adherence to on-demand or daily SSRI treatments is low. In this article, we review studies on currently available technologies that are not pharmacological, surgical, cognitive or behavioral therapies. Recent data from studies of newly developed medical devices used in PE treatment are encouraging as they provide drug-free spontaneity during coitus, without severe adverse effects.
Keyphrases
- mental health
- end stage renal disease
- healthcare
- public health
- ejection fraction
- physical activity
- newly diagnosed
- chronic kidney disease
- type diabetes
- electronic health record
- peritoneal dialysis
- case report
- metabolic syndrome
- early onset
- combination therapy
- big data
- mesenchymal stem cells
- patient reported outcomes
- case control
- health information
- adipose tissue
- social media
- artificial intelligence
- glycemic control
- insulin resistance